Malaria vaccines in development (Q36219634)

12 August 2017

1 reference

title

Malaria vaccines in development (English)

1 reference

12 August 2017

0 references

1 reference

1

W Ripley Ballou

1 reference

PubMed ID

16083325

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

3

1 reference

12 August 2017

489-503

1 reference

The global distribution of clinical episodes of Plasmodium falciparum malaria

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Genome sequence of the human malaria parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Vaccine-induced immunity to malaria parasites and the need for novel strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

DNA vaccines and their application against parasites--promise, limitations and potential solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Immunogenicity and protective efficacy of Plasmodium falciparum liver‐stage Ag‐3 in Aotus lemurinus griseimembra monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Progress in the development of recombinant and synthetic blood-stage malaria vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

The major merozoite surface protein as a malaria vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Host cell invasion by malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

The pathogenic basis of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Crystal structure of the malaria vaccine candidate apical membrane antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.489

10.1517/14728214.10.3.489

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16083325